Opportunities

As part of our corporate strategy, CytomX actively seeks strategic partnerships to advance the next generation of highly targeted antibody therapies. Such alliances not only allow us to broaden the application of our ProbodyTM platform, but also better enable us to advance the most promising drug candidates to patients and realize our vision of transforming lives with safer, more effective therapies.

If you’d like to learn more about partnering opportunities at CytomX, please contact us here.

abbvie

In 2016, CytomX entered into a strategic collaboration with AbbVie Inc. to co-develop and co-commercialize Probody drug conjugates (PDCs). Under the terms of the agreement, CytomX and AbbVie will co-develop a PDC against CD71, with CytomX leading pre-clinical and early clinical development. AbbVie will lead later development and commercialization, with global late-stage development costs shared between the two companies. AbbVie will lead global commercial activities with CytomX eligible to receive a profit share in the U.S. and tiered double-digit royalties on net product sales outside of the U.S.

CytomX retains an option to co-promote in the U.S. AbbVie also receives exclusive worldwide rights to develop and commercialize PDCs against up to two additional, undisclosed oncology targets. Existing targets in CytomX discovery, preclinical research or clinical development are not eligible for selection by AbbVie, and CytomX’s CX-072, CX-2009, and CX-188 programs remain wholly owned.

amgen

In 2017, CytomX entered into a strategic immuno-oncology collaboration with Amgen to co-develop T cell engaging bispecific therapeutics. The companies are co-developing a CytomX Probody T cell engaging bispecific against the epidermal growth factor receptor (EGFR), a highly validated oncology target expressed on multiple human cancer types, with CytomX leading early development. Amgen will lead later development and commercialization with global late-stage development costs shared between the two companies. CytomX is eligible to receive development, regulatory and commercial milestones for the EGFR program.

Amgen will lead global commercial activities with CytomX able to opt into a profit share in the U.S. and receive tiered, double-digit royalties on net product sales outside of the U.S. Existing targets in CytomX discovery, preclinical research or clinical development are not eligible for selection by Amgen, and CytomX’s CX-072, CX-2009, and CX-188 programs remain wholly owned.

Amgen also receives exclusive worldwide rights to develop and commercialize up to three additional, undisclosed targets. Should Amgen ultimately pursue all of these targets, CytomX will be eligible to receive additional upfront and milestone payments and high single-digit to mid-double digit royalty payments on any resulting products. CytomX also receives the rights from Amgen to an undisclosed preclinical T cell engaging bispecific program. Amgen is eligible to receive milestones and royalty payments on any resulting products from this CytomX program.

bms

In March 2017, CytomX and Bristol-Myers Squibb expanded their 2014 worldwide collaboration to discover, develop and commercialize novel therapies using CytomX‘s proprietary Probody platform. The collaboration provides for the selection of up to ten oncology targets and two non-oncology targets. Bristol-Myers Squibb has progressed the most advanced target under the collaboration. BMS-986249, a CTLA-4 Probody therapeutic candidate, is currently in Phase 1 testing.

Existing targets in CytomX discovery, preclinical research or clinical development are not eligible for selection by Bristol-Myers Squibb, and CytomX’s CX-072, CX-2009, and CX-188 programs remain wholly owned.

immunogen

In January 2014, CytomX entered into a multi-year, strategic collaboration with ImmunoGen, Inc. to develop PDCs for the treatment of cancer. Under the terms of the agreement, the companies will collaborate to develop PDCs against a defined number of targets.

Each company retains full development control of PDC compounds resulting from its target selection and is responsible for preclinical and clinical testing, manufacturing and commercialization.

md-anderson

In November 2015, CytomX entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (ProCAR-NK) cell therapies. Designed for more precise binding to tumors and reduced binding to healthy tissue, ProCAR-NK cell therapies will be created against targets for which safety and toxicity have traditionally been limiting factors for CAR cell therapies.

The parties will develop ProCAR-NK cell therapies against multiple undisclosed targets, and CytomX will have the option to license therapeutics that demonstrate preclinical proof of concept for clinical and commercial development.

"This is the most exciting time to be in the company because anything you do, especially when you add new capabilities, understanding and thinking to a company—it absolutely matters."

—Claus Krebber